Zoetis Inc. $ZTS Position Raised by Investment Advisory Services Inc. TX ADV

Investment Advisory Services Inc. TX ADV increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,999 shares of the company’s stock after purchasing an additional 376 shares during the period. Investment Advisory Services Inc. TX ADV’s holdings in Zoetis were worth $1,092,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Brighton Jones LLC raised its holdings in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares in the last quarter. First Hawaiian Bank raised its holdings in Zoetis by 14.0% during the first quarter. First Hawaiian Bank now owns 3,085 shares of the company’s stock worth $508,000 after purchasing an additional 379 shares in the last quarter. AdvisorNet Financial Inc raised its holdings in Zoetis by 23.0% during the first quarter. AdvisorNet Financial Inc now owns 1,642 shares of the company’s stock worth $270,000 after purchasing an additional 307 shares in the last quarter. Lantz Financial LLC raised its holdings in Zoetis by 79.7% during the first quarter. Lantz Financial LLC now owns 2,221 shares of the company’s stock worth $366,000 after purchasing an additional 985 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its holdings in Zoetis by 14.7% during the first quarter. Fifth Third Wealth Advisors LLC now owns 8,521 shares of the company’s stock worth $1,403,000 after purchasing an additional 1,095 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 1.7%

NYSE ZTS opened at $143.52 on Monday. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $197.51. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a market cap of $63.61 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 2.30 and a beta of 0.88. The firm’s 50 day moving average price is $150.35 and its two-hundred day moving average price is $155.64.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the previous year, the company posted $1.56 EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

ZTS has been the topic of several research reports. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Argus reaffirmed a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.